Long-term outcomes of Fine Needle Diathermy for established corneal neovascularisation by Hossain, P. et al.
Long-term outcomes of Fine Needle Diathermy
for established corneal neovascularisation
S Trikha,1 S Parikh,2 C Osmond,3 D F Anderson,1 P N Hossain1,2
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
bjophthalmol-2013-303729).
1Department of
Ophthalmology, University
Hospital Southampton,
Southampton, UK
2University of Southampton
School of Medicine, University
Hospital Southampton,
Southampton, UK
3MRC Epidemiology Research
Unit, University Hospital
Southampton, Southampton,
UK
Correspondence to
Mr P N Hossain, Department
of Ophthalmology, University
Hospital Southampton,
Tremona Road, Southampton
SO16 6YD, UK;
P.N.Hossain@soton.ac.uk
Received 2 June 2013
Revised 8 October 2013
Accepted 11 December 2013
To cite: Trikha S, Parikh S,
Osmond C, et al. Br J
Ophthalmol Published
Online First: [please include
Day Month Year]
doi:10.1136/bjophthalmol-
2013-303729
ABSTRACT
Background/aims Corneal neovascularisation (CoNV)
can lead to signiﬁcant ocular comorbidity with reduction
in vision and cosmesis. A number of techniques have
been described to reduce CoNV, but these can be
expensive. Our study aimed to determine the safety,
efﬁcacy and long-term outcomes of ﬁne needle
diathermy (FND) for CoNV.
Methods A 5-year retrospective study identiﬁed all
cases of FND. Indications, intraoperative complications,
and postoperative visual acuity, after treatment and
retreatments, were documented, along with the
procedure time. Evidence of regression and number of
retreatments were identiﬁed.
Results 56 eyes from 52 patients underwent FND for
CoNV. The main indications included herpes simplex
keratitis (HSK) (53%, n=25) and microbial keratitis/
peripheral ulcerative keratitis (13%, n=6). Pretreatment
acuity was signiﬁcantly correlated with extent of CoNV
(p=0.044). One complication was noted during the
procedure—an intrastromal and subconjunctival
haemorrhage (rate 2%). 68.1% of patients
demonstrated regression at ﬁrst follow-up (mean
6.9 weeks), and 89.3% (n=42) showed regression with
two or less treatments. Mean post-FND acuity was 0.72
(range −0.2–3.0) vs 0.82 (−0.2–3.0) preprocedure
(p=0.08). VA improved in the HSK subgroup (p=0.012).
Mean follow-up was 18.9 months (range 1–56 months).
Conclusions In the largest case series reported, FND
appears to be a safe and effective technique in the long
term to induce regression of CoNV, with signiﬁcant
improvement in the VA of patients with HSK.
INTRODUCTION
Corneal neovascularisation (CoNV) is a common
condition, often resulting in marked ocular morbid-
ity and a subsequent detrimental effect upon
vision. Lee et al1 found CoNV in 35 of 845 con-
secutive cases attending the eye clinic, with 12%
associated with reduced visual acuity. The process
of CoNV has been well described and is often an
innate and physiological response essential for
corneal repair and regeneration.2 Ocular surface
disease processes result in breakdown of corneal
privilege, loss of corneal clarity, scarring, and sub-
sequent deposition of lipid and calcium.2 The
follow-on effects from this are often marked dis-
comfort and a profound reduction in vision and
cosmesis.3 Furthermore, the presence of CoNV
increases the risk of subsequent corneal graft
failure, as described by a recent meta analysis pub-
lished by Bachmann et al,4 illustrating a directly
proportional relationship between graft failure and
the number of quadrants of CoNV preoperatively.5
Despite advances in the understanding of CoNV
and the emergence of topical anti-vascular endothe-
lial growth factor (VEGF) agents,6 deﬁnitive treat-
ment strategies are lacking, often due often to a
lack of effectiveness and safety, and as yet fall short
of an increasingly unmet need. Current perception
suggests the use of anti-VEGF injections is likely to
be beneﬁcial in the management of new neovascu-
larisation, leaving a gap in the treatment for estab-
lished new vessels.
A number of techniques have been described in the
literature for the treatment of CoNV. Ainslie et al
(1962) suggested conjunctival resection for recalci-
trant vessels, and in 1975 Reed et al published the
use of argon laser to occlude neovascularisation on
the cornea. Similarly, topical corticosteroids have
been suggested, by Allredge et al in 1981, to promote
regression.7–9 This does, however, carry the side
effects of increased intraocular pressure, reactivation
of possible latent infection and cataract formation. In
the current climate anti-VEGF agents have been
shown to be effective in corneal new vessel regres-
sion, however no established treatment exists for
‘established’ corneal new vessels, which do not
depend on VEGF drive to maintain patency.10 11
The principle of electrocautery to occlude vessels
dates to the 1920s, but ﬁne needle diathermy
(FND) was initially coined as an ofﬁce-based tech-
nique to occlude corneal neovascular vessels and
published by Pillai, Dua and Hossain in 2000.8
Using a 10-0 monoﬁlament nylon suture and a dia-
thermy current, direct occlusion was achieved. In a
follow-up of 14 patients over 10.3 months, 57.1%
showed evidence of regression after one treatment.
A case series of three patients published by
Wertheim et al in 20079 demonstrated an adequate
safety proﬁle, but the follow-up was 8 months and
two patients required retreatment. Thus the issues
of long-term safety and efﬁcacy have not been eval-
uated for FND. The purpose of this study was to
determine the safety, efﬁcacy and medium-term to
long-term outcomes of patients receiving FND for
established CoNV.
METHODS
The ﬁne needle diathermy technique
The decision to proceed with FND was taken on
patients with established and stable CoNV, with
diminished visual acuity and ocular surface symp-
toms. Informed consent was acquired. The periocu-
lar skin is sterilised using 5% povidone iodine for
3 min. Fifty per cent diluted iodine is used for the
ocular surface. Using an aseptic method a sterile
drape is applied and a speculum is placed with care
to move the eyelashes from the ocular surface. The
procedure is usually performed under topical, sub-
tenon or peribulbar anaesthesia.
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A 10-0 monoﬁlament nylon suture is inserted to 50% corneal
thickness (approximately 500 microns depth at the limbus)
immediately adjacent and at the proximal entry point of the
corneal new vessel into the cornea. The vessel is placed tangen-
tially, rather than parallel, to the corneal new vessel.
Monopolar electrocautery is performed using a non-
alternating current from a diathermy machine. This is applied to
the shaft of the nylon needle for 2–3 s. The circuit is composed
of the generator, active electrode, patient (via an abdominal
pad) and patient return electrode. Pathways to ground are
numerous but may include the operating table, staff members
and equipment. The patient’s cornea provides the impedance,
and heat is produced as the electrons overcome the impedance.
The electrosurgical generator works at a frequency of over
200 000 cycles per second, and coagulation setting 1 is used. A
deﬁnite endpoint of localised vascular blanching is deemed
appropriate treatment. This technique is then repeated as neces-
sary for other new vessels in the cornea. Guttae chlorampheni-
col is applied as a stat dose, and the patient discharged with
guttae chloramphenicol and Maxidex (dexamethasone 0.1%)
four times a day for 2 weeks, along with oral valaciclovir anti-
viral cover if there was a history of herpes simplex keratitis
(HSK) (see online supplementary ﬁgure S1, clip 1).
A retrospective 5-year review of all patients undergoing FND
at University Hospital Southampton (Southampton, UK) was
performed, from October 2006 to October 2011.
Baseline demographics, including age, sex and previous treat-
ments were documented. The site of surgery and the perform-
ing surgeon was retrieved, along with indication for treatment
and ocular comorbidity(ies).
Preoperatively, the severity of CoNV was quantiﬁed by the
number, depth and position of quadrant of vessels using subjective
clinical examination and digital slit lamp photography as described
by Bachmann et al (2008).4 In all cases CoNV were deemed quies-
cent. Intraoperative parameters (quadrant and number of vessels
treated) were documented. Intraoperative complications, such as
haemorrhage or corneoscleral perforation, were noted, along with
the ‘procedure time’ taken for the procedure.
Preoperative and postoperative logMAR visual acuity was identi-
ﬁed, as patients were treated (and retreated) primarily due to
CoNV encroaching on the visual axis (secondary indications for
treatment included prevention of progression, ocular discomfort
and unacceptable cosmesis). Standards of logMAR 3.0, 2.7, 2.2
and 1.8 were used for no light perception, light perception, hand
movement and count ﬁngers vision, respectively. End points of
treatment success were; the presence of ghost vessels, thinning,
reduction, absence of vessels and qualitative resolution of lipid ker-
atopathy, assessed by quantitative evaluation of the cornea and
digital slit lamp photographs. Follow-up time, evidence of treat-
ment regression and need for retreatment was recorded, with all
statistical analysis performed using Qi Macros for Microsoft Excel
2012 (QiMacros, KnowWare International, Denver, USA).
Retreatment was performed if the calibre of CoNV was
unchanged, continued to interfere with the visual axis and no
change in lipid keratopathy was observed after previous treatment.
This research adhered to the tenets of the declaration of
Helsinki. Ethics approval was not required for this study. Audit
approval was obtained from the University of Southampton
Hospitals’ National Health Service Trust Audit review board.
RESULTS
A total of 56 eyes from 52 patients underwent FND over the
speciﬁed time period. The mean age of patients undergoing the
procedure was 59.5 years (range 5–93 years, SD 18.7 years). In
order to eliminate confounding variables, all patients receiving
FND alone were included for analysis (47 eyes). This included
24 men and 23 women. Seven patients received corneal grafts
prior to the FND procedure (six—penetrating keratoplasty, one
—deep anterior lamellar keratoplasty). The most frequent indi-
cation was that of HSK (53%) (table 1). The median number of
quadrants of CoNV was two, and a mean of four vessels were
treated per procedure. A clear correlation existed between the
extent of CoNV and the preoperative visual acuity (p=0.044,
Kruskal Wallis). The mean procedure time was 21.3 min
(median 17 min, range 8–54 min, SD 10.4 min; ﬁgure 1b).
One complication was noted during the procedure—an intras-
tromal and subconjunctival haemorrhage (rate 2%). This
resolved with conservative treatment after 3 weeks. Small intras-
tromal haemorrhages were found to be common during the pro-
cedure, but were insigniﬁcant and inconsequential (ﬁgure 2).
No systemic or other ocular adverse events were identiﬁed.
Our data showed that 68% patients showed regression after
one treatment, and 89% of patients showed regression with two
or fewer treatments (table 2). The average time between treat-
ment and subsequent retreatment was 6.9 months (range 3–
15 months). The mean number of treatments was 1.44. Mean
follow-up was 18.9 months (median 11 months, range 1–
56 months, SD 13.4 months). No patient suffered a reactivation
of CoNV following FND treatment, and no patient suffered
corneal breakdown as a consequence of treatment. Five patients
underwent corneal graft surgery after FND treatment (two of
these had repeat corneal grafts and three corneal grafts for the
ﬁrst time).
VISUAL ACUITY
The mean visual acuity improved to 0.72 logMar, compared
with a pretreatment mean average of 0.82 (p=0.08, Wilcoxon
signed rank test). Insigniﬁcant correlation was found between
the extent of CoNV treated (quadrants, number of vessels) and
visual acuity outcome (Pearson’s correlation coefﬁcient −0.10).
The mean visual acuity was 1.68 after the ﬁrst treatment com-
pared with 1.51 post retreatment (p=0.49, Wilcoxon rank sum
test).
DISCUSSION
This study has demonstrated, through the largest case series,
with the longest follow-up, that FND is an effective treatment
for established mature CoNV, with 68% showing regression
after the ﬁrst treatment. For those that required retreatment, the
mean interval period was just under 7 months and principally
due to CoNVencroaching on to the visual axis or ocular surface
discomfort. Additionally FND demonstrates a satisfactory safety
proﬁle with minimal side effects, with only one intrastromal and
Table 1 Aetiology for fine needle diathermy
Aetiology n Percentage (%)
HSK 25 53.1
Microbial/peripheral ulcerative keratitis 6 12.8
Exposure keratopathy 4 8.5
Cell deficiency 4 8.5
Corneal ulcer (non-infective) 2 4.3
Rosacea keratitis 2 4.3
Allergic eye disease 4 8.5
HSK, herpes simplex keratitis.
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subconjunctival haemorrhage which resolved after 3 weeks.
Overall, the procedure appears to be safe, rapid, cost effective
(ie, requiring minimal equipment) and clinically effective. The
most signiﬁcant improvement in visual acuity was demonstrated
in the HSK subgroup (table 3, ﬁgure 2) although a correlation
existed between extent of CoNV and visual acuity preprocedure,
the limitation in acuity improvement in all groups may vary due
to the underlying pathological mechanisms, rather than CoNV
resolution alone. Importantly, our mean follow-up was
18.9 months (range 1–56 months), and with the mean time for
retreatment 6.9 months this therefore captures the patients
requiring retreatment. No clinically observed cases of corneal
ectasia were observed post treatment. The procedure is short
and could be performed in an ofﬁce based setting.
The data compares favourably with the original study by Pillai
et al, who demonstrated a 57.1% success rate after one treat-
ment. In this case series of 14 patients, 3 intrastromal haemor-
rhages and 1 crystalline deposit were detected.8 Similarly, Thatte
et al12 highlighted a success rate of 100% after one treatment in
28 cases. The mean follow-up in this series was only 6 months
in comparison with our study (18.9 months).
Limitations of our study include its retrospective nature, and
an absence of a control group. Similarly, certain subgroups were
small (n=2). The analysis of the effect upon visual acuity could
be improved through multivariate regression analysis as ocular
comorbidity is a variable that may have been disproportionately
less in the HSK subgroup compared with others. Our study
could also have been improved by the assessment of corneal sen-
sitivity, as a neurotrophic component may explain effect on efﬁ-
cacy of FND treatment. Acuity improvement in HSK could be
hypothetically explained as while FND may reduce established
CoNV, coexisting treatment with anti-inﬂammatories and anti-
viral agents may result in a decrease in neutrophil recruitment,
interleukin (IL)-6 and IL17-A driven VEGF A production.13 14
Correspondingly, the absence of viral replication could enhance
the production of sVEGFR-1, which binds to VEGF and pre-
vents angiogenesis.13 15
A high number of treatments were performed on patients
with lipid keratopathy which contained established vessels and
all cases the lipid keratopathy improved. An improvement in
acuity in the HSK group may also have been due to unbalanced
Figure 2 Scatterplot (logMar visual acuity (VA)) comparing Pre and
Post ﬁne needle diathermy visual acuity for the herpes simplex keratitis
subgroup.
Table 2 The effect of FND on corneal NV regression
FND Treatments to achieve regression Number (%)
1 27 (57.4)
2 15 (31.9)
3 5 (10.6)
FND, fine needle diathermy.
Figure 1 (A) Pretreatment. (B) Day 1 postoperatively. (C) 12 months
post-treatment demonstrating marked regression of vessels and lipid
keratopathy.
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reduction in lipid keratopathy and less corneal oedema in the
optical zone. Our study was not powered to determine statistic-
ally signiﬁcant differences in acuity, and therefore must be inter-
preted with caution. However, Bachmann et al’s16 meta-analysis
of anticorneal angiogenic therapies purported weak correlation
between a reduction in CoNV and association with an improve-
ment in visual acuity, and recommended further prospective ran-
domised controlled trials, including morphological analysis of
vascularisation forms and its effect upon acuity.16 It is likely that
a larger trial would determine FND’s efﬁcacy in patients with
HSK.
The extent of CoNV regression and need for retreatment may
be affected by interobserver variability, as the power setting,
time and manipulation of the diathermy electrode would be
varied by the individual operating surgeon. The agreement of a
deﬁnitive end point (that of localised blanching) does minimise
this. Visual outcome is likely to have been affected by multiple
ocular comorbidities, requiring multivariate analysis to deter-
mine the FND effect, although all patients requiring FND and
other treatment interventions were excluded from our analysis.
In addition, qualitative analysis of patient symptomatology
revealed that most patients experienced less ocular surface
discomfort post FND, and our study could be improved by
the statistical analysis of a formalised Visual Function
Questionnaire-25, correlated with preprocedure and postproce-
dure measurements of ocular surface tear ﬁlm stability.
Research into the inhibition of CoNV continues apace, with
anti-VEGF therapies (such as bevacizumab, ranibizumab and
pegaptanib), VEGF-trap, siRNA and VEGF signalling tyrosine
kinase inhibitors emerging as a leading treatment modality for
‘new’ CoNV.13 14 17 It is thought that inﬂammation induces
VEGF-A production by a variety of cell types including macro-
phages and T cells.14 18 19 A pilot study by Koenig et al,10 in
which 16 eyes from 16 patients received diathermy vessel coagu-
lation followed by treatment for up to 4 weeks with topical bev-
acizumab ﬁve times daily, demonstrated regression in 14 eyes.13
Patients were followed up for a mean of 276 days (range 29–
464 days).10 16 On balance, Stevenson’s data suggest that ranibi-
zumab’s effects upon CoNV may be modestly superior when
compared with bevacizumab’s, with a statistically signiﬁcant
decrease in neovascular area noted in week 3 post treatment
with ranibizumab (compared with week 6 with bevacizumab),
although the authors recognised a pressing need for a
head-to-head multicentre randomised controlled trial.20
Petsoglou et al21 have demonstrated a statistically signiﬁcant
regression of corneal new vessels with three injections of
bevacizumab compared with saline placebo. No adverse events
were noted with either ranibizumab or bevacizumab use topic-
ally, although the most effective route of administration (topic-
ally, subconjunctivally or intracamerally) is yet to be
elucidated.13 Rosenstein et al22 do, however, caution that the
inhibition of ocular surface anti-VEGF may induce neurotrophic
keratopathy inhibiting VEGF-mediated neural growth.13
The optimal assessment and treatment of CoNV is yet to be
fully elucidated, with dose, duration and the timing of treat-
ments not uniformly agreed upon. By using a standardised
grading scale preoperatively and postoperatively, as has been
suggested by Bock et al,7 a more accurate treatment effect could
be identiﬁed. Further reﬁnement of imaging techniques that
would allow assessment of vascular depth and quantiﬁcation of
vascular dynamics would be highly welcome. Indeed indocya-
nine green and fundus ﬂuorescein angiography, along with in
vivo confocal microscopy use, may serve as valuable tools in
which to assess the extent of CoNV, and be useful to evaluate
treatment.23
Corneal disease is noted to be a leading cause of non-
refractive visual impairment worldwide, second only to cata-
ract.19 24 A gathering body of evidence suggests that antiangio-
genic agents will play a pivotal role in the future, particularly
for ‘new’ neovascularisation as this has been shown to be most
responsive to VEGF blockade.4 10 16 However, comparatively
little is known about the nature of neovascularisation with dif-
ferent underlying aetiologies, and therefore neovascularisation
responsiveness may differ across conditions.16 The actual effect
of intervention may be calculated more accurately via the
standardisation of neovascularisation quantiﬁcation methods.16
Earlier intervention may help avoid the potentially serious
complications of CoNV and for established deep and ‘feeder’
vessels, anti-VEGF may not be of beneﬁt.13 While early work
by Jo et al has demonstrated promising regression of estab-
lished neovascularisation using coblockade of VEGF-A and
platelet derived growth factor (PDGF)-β, this has not been
used in humans.13 We postulate that FND may be an ofﬁce-
based, inexpensive, useful, safe and effective treatment modal-
ity for established, mature corneal new vessels, as an adjunct
to anti-VEGF use or for those recalcitrant to anti-VEGF
blockade.
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